Iovance Biotherapeutics Partners with TrakCel for Personalized Patient Product Management
11 September 2017 - 10:00PM
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) and TrakCel Ltd. today
announced a partnership to build a scheduling and logistics tool
that automates the supply chain for Iovance’s adoptive cell therapy
products that utilize its tumor-infiltrating lymphocyte (TIL)
technology. The TrakCel Solution will electronically link Iovance
with clinical sites, contract manufacturing organizations and
couriers to schedule and track TIL therapies for each patient. The
TrakCel Solution is intended to help manage capacity utilization
and throughput and will provide efficiencies in the delivery of TIL
treatment.
“As we expand our clinical program and further them into
later-stage development and ultimately prepare for
commercialization, we are entering the partnership with TrakCel to
better manage the chain of identity for patient tumor samples and
our TIL products. We selected TrakCel since the organization is a
global leader in supply chain management for cell products,” said
Dr. Maria Fardis, PhD, MBA, President and Chief Executive Officer
of Iovance Biotherapeutics. “Real time scheduling can be done
through this system, once implemented, allowing for ease of
scheduling by the physician and administrator of the TIL product.
Real time tracking of patient material can be done by Iovance
through an integrated bar-code as well.”
Commenting on the partnership with Iovance, Ravi Nalliah,
TrakCel’s CEO said, “TrakCel’s technology was developed to support
companies as they scale up their therapies for late clinical
development and commercial delivery. Cell therapy supply chains are
complex and involve multiple stakeholders from cell or tumor sample
collection, through manufacturing, to infusion of drug product and
this complexity grows as patient numbers increase as products
approach commercialization. Close management and scheduling of
activities across this complex supply chain is essential to
delivering an efficiently produced, safe and effective product,
which in turn can help drive the commercial success of a cell
therapy. We are delighted that Iovance has chosen TrakCel to
support the clinical development and commercialization of their
transformative TIL technology.”
About Iovance Biotherapeutics, Inc. Iovance
Biotherapeutics, Inc. is a clinical-stage biotechnology company
focused on the development of cancer immunotherapy products for the
treatment of various cancers. The Company's lead product candidate
is an adoptive cell therapy using tumor-infiltrating lymphocyte
(TIL) technology being investigated for the treatment of patients
with metastatic melanoma, recurrent and/or metastatic squamous cell
carcinoma of the head and neck and recurrent and metastatic or
persistent cervical cancer. For more information, please
visit http://www.iovance.com.
About TrakCel Ltd.TrakCel is
the market leading designer, developer and deliverer of integrated
technologies specifically created in 2012 to manage the
international autologous and allogeneic cell, gene and
immunotherapy supply chain. TrakCel's software platform has
been developed in collaboration with, and increasingly adopted by
leading companies in the cell, gene and immunotherapy industries.
TrakCel’s solutions deliver real-time control over the entire
therapeutic supply chain, from sample collection through
manufacturing to cell product delivery. The TrakCel platform
accelerates global scale-up and scale-out of cell and gene therapy
products, increasing efficiency and decreasing complexity, while
maintaining needle-to-needle compliance and traceability.
Forward-Looking Statements Certain matters
discussed in this press release are “forward-looking statements”.
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “continue,” “estimates,” “anticipates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “will,” “should” or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. In particular, the
Company’s statements regarding trends and potential future results
are examples of such forward-looking statements. The
forward-looking statements include risks and uncertainties,
including, but not limited to, the success, timing and cost of our
ongoing clinical trials and anticipated clinical trials for our
current product candidates, including statements regarding the
timing of initiation and completion of the trials; the timing of
and our ability to obtain and maintain U.S. Food and Drug
Administration or other regulatory authority approval of, or other
action with respect to, our product candidates; the strength of
Company’s product pipeline; the successful implementation of the
Company’s research and development programs and collaborations; the
success of the Company’s license or development agreements; the
acceptance by the market of the Company’s product candidates, if
approved; and other factors, including general economic conditions
and regulatory developments, not within the Company’s control. The
factors discussed herein could cause actual results and
developments to be materially different from those expressed in or
implied by such statements. A further list and description of
the Company’s risks, uncertainties and other factors can be found
in the Company’s most recent Annual Report on Form 10-K and the
Company's subsequent filings with the Securities and Exchange
Commission. Copies of these filings are available online at
www.sec.gov or www.iovance.com. The forward-looking statements are
made only as of the date of this press release and the Company
undertakes no obligation to publicly update such forward-looking
statements to reflect subsequent events or circumstance.
Iovance Investor Relations Contact: Sarah
McCabeStern Investor Relations,
Inc.212-362-1200sarah@sternir.com
Iovance Media Relations Contact:Evan
Smith/Kotaro YoshidaFTI Consulting212-850-5622/212-850-5690
evan.smith@fticonsulting.comkotaro.yoshida@fticonsulting.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Apr 2024 to May 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From May 2023 to May 2024